Literature DB >> 12356584

Association of genetic defects in primary resected lung adenocarcinoma revealed by targeted allelic imbalance analysis.

Florence Cave-Riant1, Benoit Cuillerier, Michèle Beau-Faller, Nadine Martinet, François Alla, Christian Bronner, Anne Schneider, Pierre Oudet, Marie Pierre Gaub.   

Abstract

Genetic mechanisms underlying origin and progression of lung cancer are still poorly understood, despite the numerous studies which identified many genomic alterations. Using polymorphic microsatellites, allelic imbalances have been frequently found at loci such as 3p, 5q, 8p, 9p and 9q, 11p and 11q, and 17q without either histologic specificity or prognosis value. We report allelotyping results in 54 cases (50 smokers) of primary lung adenocarcinoma (50 men/4 women) resected at one institution. To perform this study, a panel of seven microsatellites were chosen upon their likely involvement in lung cancer or in the cell cycle. A highly sensitive method was designed using fluorescent PCR coupled with quantification on an automated DNA sequencer. We report that at least one allelic imbalance was observed in 87% of adenocarcinoma. Alterations at 17q23 tended to be associated with early stage tumors (I and II) and longer survivals (P = 0.05 and P = 0.06, respectively). Furthermore, concomitant alterations were found at 9p21 and at either 9q34 or 3p24 loci (P = 0.003 and P = 0.004, respectively). The presence of genes coding for TGF-beta receptors I and II at these loci suggests that the TGF-beta/CDK inhibitor P16/P15 signaling pathway might be involved in lung adenocarcinoma development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12356584     DOI: 10.1165/rcmb.4800

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  1 in total

1.  STRAD in Peutz-Jeghers syndrome and sporadic cancers.

Authors:  W W J de Leng; J J Keller; S Luiten; A R Musler; M Jansen; A F Baas; F W M de Rooij; J J P Gille; F H Menko; G J A Offerhaus; M A J Weterman
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.